These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 6940248)

  • 21. Effects of nonionic surfactants on the physical stability of immunoglobulin G in aqueous solution during mechanical agitation.
    Vidanovic D; Milic Askrabic J; Stankovic M; Poprzen V
    Pharmazie; 2003 Jun; 58(6):399-404. PubMed ID: 12857003
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling.
    van den Bongard HJ; Mathôt RA; van Tellingen O; Schellens JH; Beijnen JH
    Cancer Chemother Pharmacol; 2002 Jul; 50(1):16-24. PubMed ID: 12111107
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients.
    van Tellingen O; Huizing MT; Panday VR; Schellens JH; Nooijen WJ; Beijnen JH
    Br J Cancer; 1999 Sep; 81(2):330-5. PubMed ID: 10496361
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Study for modifying activity of solvents on antitumor activity of paclitaxel].
    Fujimoto S
    Gan To Kagaku Ryoho; 1994 Apr; 21(5):665-70. PubMed ID: 7908793
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL.
    Sparreboom A; van Tellingen O; Nooijen WJ; Beijnen JH
    Cancer Res; 1996 May; 56(9):2112-5. PubMed ID: 8616858
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Local reactions to i.v. diazepam in three different formulations.
    Schou Olesen A; Hüttel MS
    Br J Anaesth; 1980 Jun; 52(6):609-11. PubMed ID: 7426232
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients.
    Malingré MM; Schellens JH; Van Tellingen O; Ouwehand M; Bardelmeijer HA; Rosing H; Koopman FJ; Schot ME; Ten Bokkel Huinink WW; Beijnen JH
    Br J Cancer; 2001 Nov; 85(10):1472-7. PubMed ID: 11720431
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development and characterization of a novel Cremophor EL free liposome-based paclitaxel (LEP-ETU) formulation.
    Zhang JA; Anyarambhatla G; Ma L; Ugwu S; Xuan T; Sardone T; Ahmad I
    Eur J Pharm Biopharm; 2005 Jan; 59(1):177-87. PubMed ID: 15567316
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Methods for preventing reactions secondary to Cremophor EL.
    Michaud LB
    Ann Pharmacother; 1997 Nov; 31(11):1402-4. PubMed ID: 9391700
    [No Abstract]   [Full Text] [Related]  

  • 30. Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo.
    Sparreboom A; Verweij J; van der Burg ME; Loos WJ; Brouwer E; Viganò L; Locatelli A; de Vos AI; Nooter K; Stoter G; Gianni L
    Clin Cancer Res; 1998 Aug; 4(8):1937-42. PubMed ID: 9717822
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The removal of Cremophor EL from paclitaxel for quantitative analysis by HPLC-UV.
    Perdue JD; Seaton PJ; Tyrell JA; DeVido DR
    J Pharm Biomed Anal; 2006 Apr; 41(1):117-23. PubMed ID: 16324815
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A case of allergic contact dermatitis to polyglyceryl laurate.
    Washizaki K; Kanto H; Yazaki S; Ito M
    Contact Dermatitis; 2008 Mar; 58(3):187-8. PubMed ID: 18279173
    [No Abstract]   [Full Text] [Related]  

  • 33. The polyoxyethylene castor oil Cremophor EL modifies multidrug resistance.
    Schuurhuis GJ; Broxterman HJ; Pinedo HM; van Heijningen TH; van Kalken CK; Vermorken JB; Spoelstra EC; Lankelma J
    Br J Cancer; 1990 Oct; 62(4):591-4. PubMed ID: 2223576
    [No Abstract]   [Full Text] [Related]  

  • 34. [Studies on the stability of polyoxyethylene castor oil EL-40 and tween 80 in calciferol solubilized systems].
    Liu CT; Qi L
    Yao Xue Xue Bao; 1987 Sep; 22(9):694-9. PubMed ID: 3502220
    [No Abstract]   [Full Text] [Related]  

  • 35. Paclitaxel-induced nail changes: possible role of its vehicle (Cremophor EL).
    Minutilli E; Izzo F; Natoli G; Psaila A; Di Filippo F; Terzoli E
    Eur J Dermatol; 2006; 16(6):693-4. PubMed ID: 17229616
    [No Abstract]   [Full Text] [Related]  

  • 36. Entrapment by Cremophor EL decreases the absorption of paclitaxel from the gut.
    Bardelmeijer HA; Ouwehand M; Malingré MM; Schellens J; Beijnen JH; van Tellingen O
    Cancer Chemother Pharmacol; 2002 Feb; 49(2):119-25. PubMed ID: 11862425
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Delayed seizure associated with paclitaxel-Cremophor el in a patient with early-stage breast cancer.
    O'Connor TL; Kossoff E
    Pharmacotherapy; 2009 Aug; 29(8):993-6. PubMed ID: 19637953
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Histamine release and hypotensive reactions in dogs by solubilizing agents and fatty acids: analysis of various components in cremophor El and development of a compound with reduced toxicity.
    Lorenz W; Schmal A; Schult H; Lang S; Ohmann C; Weber D; Kapp B; Lüben L; Doenicke A
    Agents Actions; 1982 Apr; 12(1-2):64-80. PubMed ID: 6177219
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anaphylactoid reactions associated with parenteral cyclosporine use: possible role of Cremophor EL.
    Howrie DL; Ptachcinski RJ; Griffith BP; Hardesty RJ; Rosenthal JT; Burckart GJ; Venkataramanan R
    Drug Intell Clin Pharm; 1985 Jun; 19(6):425-7. PubMed ID: 4006735
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Presumed anaphylactic shock after infusion of Lipofundin].
    Andersen HL; Nissen I
    Ugeskr Laeger; 1993 Jul; 155(28):2210-1. PubMed ID: 8328083
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.